This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Friday, November 15, 2013
Watch - Sofosbuvir, ribavirin therapy after liver transplant shows positive results for HCV patients
Sofosbuvir, ribavirin therapy after liver transplant shows positive results for HCV patients
November 15, 2013
WASHINGTON — Combined sofosbuvir and ribavirin therapy to treat established recurrent hepatitis C infection after liver transplant has proven successful in preliminary results, according to research presented by Michael R. Charlton, MD, in a late-breaking abstract at The Liver Meeting.
The ongoing single-arm, open-label interferon-free pilot study enrolled 40 naive and treatment-experienced patients with recurrent HCV infection of any genotype after liver transplantation. The patients received up to 24 weeks of sofosbuvir and ribavirin with a primary endpoint of sustained virologic response 12 weeks after completion of treatment.
Full Story »
No comments:
Post a Comment